Clinical Trial Update: Iodixanol vs. Iomeprol to Prevent Contrast-Induced Nephropathy After Coronary Intervention (CONTRAST) [Phase 4]

View source ↗

Summary

Phase 4 trial comparing iodixanol versus iomeprol for prevention of contrast-induced nephropathy after percutaneous coronary intervention has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Coronary Artery Disease

Drugs mentioned

• Iomeron (iomeprol)
• VISIPAQUE (IODIXANOL)

Snippet

Sponsor: Deutsches Herzzentrum Muenchen | Conditions: Renal Insufficiency, Chronic, Angioplasty, Transluminal, Percutaneous Coronary | Phase 4 | Status: COMPLETED